|
Co-Founder and Board member, has extensive, global experience in large pharmaceutical and biotechnology companies. She served as CEO of Kinexis from 2001 to 2005 and from 1998 to 2001, Dr. Kilian was the Vice-President, Research, Pharmacia Corporation, Stockholm , Sweden . Under her leadership the Metabolic Diseases Division successfully advanced novel drug candidates for treatment of type 2 diabetes/obesity into development. Dr. Kilian led the Swedish operation during the successful spin-off of this Pharmacia Division to become a new, independent, privately owned biotech company, Biovitrum AB. Prior to joining Pharmacia, Dr. Kilian was Department Head, Cell Physiology, Glaxo, Research Triangle Park , North Carolina . One of her major assignments while at Glaxo was to initiate and implement an innovative genomics program in type 2 diabetes. During her earlier employment at Hoffmann-La Roche, Nutley, New Jersey , Dr. Kilian established an international reputation for her work in cytokine drug discovery research and gained experience in the discovery and development of both small molecule and protein therapeutics for treatment of immune and inflammatory disorders. In addition to her pharmaceutical experience, Dr. Kilian was the Vice-President, R & D, at the start-up company, gene/Networks, Alameda , California , focusing on the discovery of the genetic targets for diabetes, obesity and other multi-factorial disorders. | 